Dr. Shuo Ma on Non-Chemotherapy Regimens for Hematologic Malignancies

February 20, 2015

Conference | PER® Congress on Hematologic Malignancies (Winter Hematology®)

Shuo Ma, MD, PhD, assistant professor at Northwestern University in the Robert H. Lurie Comprehensive Cancer Center discusses advances in non-chemotherapy regimens for patients with hematologic malignancies.

Shuo Ma, MD, PhD, assistant professor at Northwestern University in the Robert H. Lurie Comprehensive Cancer Center, discusses advances in non-chemotherapy regimens for patients with hematologic malignancies.

Rituximab in combination with bortezomib and rituximab in combination with lenalidomide have shown success for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma . Both combinations provide a fairly high response rate in both the frontline setting and the relapse setting, says Ma.

B-cell receptor pathway inhibitors including ibrutinib and idelalisib also offer exciting benefits. Both have shown significant activity across many different forms of b-cell malignancies.

<<<